Recent evidence has suggested that pediatric patients treated with (PEG) IFNα-dominant therapy achieve HBsAg loss rates ranging from 20% to 50%, and initiating antiviral therapy early in the disease course predicts greater treatment benefits.[3,4] Notably, a prospective real-world study demonstrated that 14 pediatric patients with S3/4 fibrosis exhibited significant improvement in liver histology with lamivudine (LAM) combined with IFNα therapy, irrespective of HBsAg loss.[5] However, data for patients under 1 year of age are limited. Here, IFNA2 is linked to fibrosis.